A previously unidentifiable type of low-grade inflammation may explain why common anti-inflammatory drugs such as aspirin have shown promise against some types of cancer – even when patients don’t display typical signs of inflammation.  A team led by researchers in the labs of Atul Butte, MD, PhD, director of the Institute for Computational Health SciencesContinue reading “Para-inflammation can drive the formation of tumors, aspirin stops it”